Quick Answer
enGene Therapeutics Inc. reported Operating Income of -$123.17 million for fiscal year 2025.
enGene Therapeutics Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$123.17M | -97.7% |
| 2024 | -$62.30M | -139.1% |
| 2023 | -$26.06M | -34.1% |
| 2022 | -$19.43M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| January 31, 2026 | -$31.18M | -17.2% | -4.1% |
| July 31, 2025 | -$29.95M | -78.7% | -10.4% |
| April 30, 2025 | -$27.12M | -56.7% | -1.9% |
| January 31, 2025 | -$26.61M | -147.0% | -58.8% |
| July 31, 2024 | -$16.76M | -168.2% | +3.2% |
| April 30, 2024 | -$17.31M | -265.4% | -60.7% |
| January 31, 2024 | -$10.77M | -132.5% | -72.4% |
| July 31, 2023 | -$6.25M | — | -31.9% |
- enGene Therapeutics Inc. showed a decrease of -97.7% in Operating Income compared to the prior fiscal year.
- Over the 2022–2025 period, enGene Therapeutics Inc.’s operating income has declined by 534.0% (from -$19.43 million to -$123.17 million).
- The most recent figure is from enGene Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on December 22, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: